 | Up a level |
2021
Nathan, Paul, Hassel, Jessica C., Rutkowski, Piotr, Baurain, Jean-Francois, Butler, Marcus O., Schlaak, Max, Sullivan, Ryan J., Ochsenreither, Sebastian, Dummer, Reinhard, Kirkwood, John M., Joshua, Anthony M., Sacco, Joseph J., Shoushtari, Alexander N., Orloff, Marlana, Piulats, Josep M., Milhem, Mohammed 
ORCID: 0000-0003-4663-6824, Salama, April K. S., Curti, Brendan, Demidov, Lev, Gastaud, Lauris, Mauch, Cornelia, Yushak, Melinda, Carvajal, Richard D., Hamid, Omid, Abdullah, Shaad E., Holland, Chris, Goodall, Howard and Piperno-Neumann, Sophie
(2021).
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
N. Engl. J. Med., 385 (13).
S. 1196 - 1207.
WALTHAM:
MASSACHUSETTS MEDICAL SOC.
ISSN 1533-4406
2020
Dummer, Reinhard, Sandhu, Shahneen Kaur, Miller, Wilson H., Butler, Marcus O., Blank, Christian U., Munoz-Couselo, Eva, Burris, Howard A., III, Postow, Michael A., Chmielowski, Bartosz, Middleton, Mark R., Berking, Carola, Hassel, Jessica Cecile, Gesierich, Anja, Mauch, Cornelia, Kleha, Joseph, Gollerkeri, Ashwin, Harney, Allison, Pickard, Michael D. and Ascierto, Paolo Antonio (2020). A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755